COVISHIELD - product monograph
Health Canada has reviewed the manufacturing information for these vaccines and found them to be comparable.
- Individuals 18 years and older
- 2x 0.5 ml doses given IM (preferably deltoid)
- The 2nd dose should be given between 4 and 12 weeks after the 1st
- NOTE: As of March 3, 2021, NACI recommends that in the context of limited COVID-19 vaccine supply, jurisdictions should maximize the number of individuals benefiting from the first dose of vaccine by extending the interval for the second dose of vaccine to 4 months. This recommendation is subject to revision as evidence evolves.
Only short to medium term data are available at this time. Surveillance will continue for long-term adverse effects.
The most commonly reported adverse effects included:
- injection site tenderness
- injection site pain
- There are no known drug interactions.
- Under 18 years of age
- The COVISHIELD vaccine is approved for use in persons 18 years of age and older.
- History of anaphylaxis following previous dose of the vaccine.
- Reported hypersensitivity to one of the ingredients. See product monograph for ingredients.
- Other information will be added as it becomes available from NACI.
- Currently feeling unwell with symptoms that could be COVID-19.
- to avoid confusion if symptoms arise/worsen as they could be adverse effects of the vaccine or because of the underlying infection
- to prevent potential transmission to others who are at the vaccine clinic/site (clients should be following public health quarantine recommendations)
- Serious adverse or allergic reaction to previous dose of COVID-19 vaccine unless determined safe by an allergist or other healthcare provider.
Other information will be added as it becomes available from NACI.
- Clients with current infection should not present for vaccination to prevent transmission to others at the vaccination clinic/site and should follow public health quarantine recommendations.
- If acute symptoms have resolved and all quarantine orders have been followed, the client can be vaccinated.
- However, the recommendation is for clients to wait 3 months to take advantage of the client's natural immunity and to leave the current supply of vaccine for others without immunity.
- Trial included <10% participants with COVID-19 infection proven by serology.
- The COVID-19 vaccines should be administered at least 14 days AFTER any other vaccines (live or inactivated).
- Other vaccines should be avoided for 28 days AFTER receiving the last COVID-19 vaccine dose.
- Exception: If a patient requires a vaccination as part of a post-exposure prophylaxis protocol, it should be administered.